[Skip to Navigation]
Views 1,166
Citations 0
News From the JAMA Network
August 3, 2021

Is Dapagliflozin Cost-effective for Treating Heart Failure?

JAMA. 2021;326(5):378. doi:10.1001/jama.2021.12116

Dapagliflozin offers intermediate value for patients who have heart failure with reduced ejection fraction (HFrEF), regardless of diabetes or health-impairment status, according to a recent economic analysis. “[G]iven evidence of clinical benefit and economic value, focus should be on increasing therapy rates among patients who have HFrEF with and without diabetes,” the authors wrote in JAMA Cardiology.

×